About Us
Our Story
Argonaut was founded by a team with more than 200 years of combined experience leading global CDMOs. After decades of supporting complex injectable programs, we set out to build the kind of partner we believed sponsors deserved—one that combines technical expertise, operational flexibility, and exceptional quality to support products from preclinical development through commercial manufacturing.
Everything about Argonaut was designed with that vision in mind. Our infrastructure supports modern aseptic manufacturing and evolving global regulatory expectations, including the latest EU Annex 1 guidance. Our manufacturing strategies are built to maximize product yield while protecting product quality, and our experienced team works alongside each client to develop an approach tailored to their unique program, timeline, and technical requirements. As your product advances, we provide the flexibility to adapt without compromising the quality, compliance, or consistency you rely on.
Our goal is to be more than a manufacturer. We strive to be a long-term partner. By combining modern facilities, experienced people, and a collaborative approach, we help simplify development, reduce manufacturing risk, and support your product from its earliest stages through commercial success.
Why Sponsors Choose Argonaut
We’ve built Argonaut around the principles that matter most to our clients: quality, flexibility, technical expertise, and long-term partnership. Our approach combines modern manufacturing, experienced people, and collaborative project execution to support even the most demanding sterile injectable programs.
At Argonaut, we’re committed to:
- Supporting your product from preclinical development through commercial manufacturing
- Maintaining the highest standards of quality and regulatory compliance
- Maximizing product yield
- Adapting to the unique requirements of your program
- Simplifying your pipeline through an integrated partner network
- Providing an experienced team invested in your success
Our Leadership Team
The strength of Argonaut starts with the people behind it. Our leadership team brings more than 200 years of combined experience leading global CDMOs where they helped build world-class manufacturing organizations and successfully navigated more than 40 FDA Pre-Approval Inspections (PAIs). Today, that experience guides our approach to quality, compliance, and client partnerships.
Built For Modern Sterile Manufacturing
Argonaut’s 90,000-square-foot manufacturing campus spans three facilities within 5 miles of each other in Carlsbad, CA.
Learn more about our facilities and technologies that support our sterile manufacturing operations on our Facilities page.
5925 Priestly Dr
2841 Loker Ave
1900 Aston Ave
We’d love to give you a tour.
An Engaged Board of Directors & Advisors
Argonaut is guided by an experienced Board of Directors and Advisors who provide strategic oversight, technical expertise, and industry insight. Together, they help shape our long-term vision, strengthen our commitment to quality, and support our mission of delivering exceptional sterile manufacturing solutions for our clients.
Paul Grossman, Ph.D.
Before joining Telegraph Hill Partners, Paul Grossman was Head of Strategy and Corporate Development for Life Technologies, holding a similar position at Invitrogen Corporation prior to the merger with Applied Biosystems. Paul has held a variety of leadership and executive roles in R&D, Legal and Corporate Development teams, including spearheading the acquisition or divestment of more than 25 businesses
View Profile
Alex Herzick
Before joining Telegraph Hill Partners, Alex worked at Genzyme Corporation in the Oncology / Multiple Sclerosis Business Development Group, where he sourced, evaluated, and executed strategic M&A and licensing biopharma transactions. Prior to Genzyme, he worked as a portfolio manager at BlueMountain Capital Management, and as an investment banking analyst at Bank of America Securities.
View Profile
Todd Holmes
Todd is the Founder and Managing Partner of NewVale Capital LLC. He has more than 20 years of life science investing, company-building, and transaction experience across private and public sectors. Before founding NewVale, Todd led pharma and pharma services investing at CRG LP. Prior to CRG, he held senior investment roles with Gurnet Point Capital and Third Rock Ventures, helping to build and grow life science companies. Earlier in his career, he was an investor with BVF Partners, a biotechnology-focused hedge fund.
View Profile
Scott Waldman
Scott has led and advised life sciences companies for more than 25 years with a focus on CDMOs since 2010. Scott consults for the pharma services industry and is an Operating Partner with NewVale Capital. Scott previously led M&A and corporate strategy as SVP of corporate development at Curia and as Chief Strategy Officer / Head of M&A at Lonza. Scott also served as US general counsel for Lonza and general counsel for Enzon Pharmaceuticals. He began his career as a corporate/M&A lawyer in New York at Sidley Austin and Weil, Gotshal & Manges.
View Profile
Argonaut: Your Formulation for Success
We built Argonaut to be the kind of fill-finish partner we’d want to work with, and we bring that philosophy to every client and every program. We’re invested in your success because every milestone achieved brings innovative therapies one step closer to the patients who need them.